Abstract:Introduction Amyloid transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, systemic, life-threatening disease, characterized by both cardiac and extra-cardiac symptoms and signs. Its diagnosis remains challenging, however it is increasingly being pursued due to the availability of non-invasive diagnostic means, namely bone scintigraphy. Data regarding the prevalence of ATTR-CM in Greece are scarce. Purpose We aimed to study the prevalence and characteristics of ATTR-CM, both wild-type (ATTRwt-CM) and hereditary (ATTRv-CM), in patients with left ventricular hypertrophy (LVH) of undetermined etiology in Greece. Methods RETTRACE is an on-going, low- risk, prospective, multicenter, nationwide descriptive study, in 14 major outpatient Cardiology centers throughout Greece. Its primary endpoint is the prevalence of ATTR-CM in adults ≥ 50 years, with: a) Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and a left ventricular wall thickness (LVWT) of ≥12mm, or b) a LVWT ≥14 mm of unknown etiology. Secondary endpoints include the prevalence of ATTRv-CM, the description of clinical characteristics of ATTR-CM patients, and their quality of life, as evaluated with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the EuroQol-5-Dimensions Questionnaire (EQ-5D-3L). Patients were screened and managed according to local clinical practice. Screening for light chain (AL) amyloidosis was done by immunofixation electrophoresis (serum and urine) and serum free light-chain (sFLC) assay, while biopsy was performed at the investigator's discretion. TTR genotyping was done centrally. Results The RETTRACE interim analysis (data-cut-off: May 31st, 2023), includes 153 patients (men: 52,9%), with a mean (SD) age of 77 (10.3) years. Basic demographics are shown in Table 1. Amongst patients who had bone scintigraphy results available, 71 (51.4%) were grade 0 according to the Perugini score. Furthermore, 62 tests of grades 1-3 were assessed by two independent reviewers and their final consensus was used to estimate the primary endpoint. In total, 24 out of 134 eligible patients were deemed to have ATTR-CM (17.9%), per applied criteria. Two of them carried mutations (Val114Ala and Ala101Thr respectively). As compared to non-ATTR-CM patients, those with ATTR-CM were older (mean age of 82.9 vs 76.0 years, p=0.004), less frequently hypertensive (54.2% vs 78.2%, p=0.021) and had more frequently undergone carpal tunnel surgery (29.2% vs 10.0%, p=0.021). Moreover, they had a poorer quality of life by MLHFQ (median 19.5 vs 40.0, p=0.05), while no significant differences were found in the EQ-5D-3L questionnaire. Conclusions ATTR-CM has a significant prevalence in a Greek population of adults ≥ 50 years with LVH of undetermined etiology. RETTRACE study results will provide valuable information for this underdiagnosed, life-threatening condition.

Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis

Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography

Advanced Echocardiographic Assessment in Transthyretin Amyloidosis: Early Phenotype Markers in Mutation Carriers

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis

Cardio-Hepatic Interaction in Cardiac Amyloidosis

Phenotype and prognostic factors in geriatric and non‐geriatric patients with transthyretin cardiomyopathy

Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Prevalence of cardiac amyloidosis among elderly patients with recent-onset atrial fibrillation. The PREVAL-ATTR study.

Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis

Prevalence and prognostic significance of restriction versus systolic dysfunction in patients with transthyretin and light chain cardiac amyloidosis

Descriptive study of the clinical and myocardial status of a population with anatomopathological aortic valve amyloidosis

ATTR cardiac amyloidosis after lumbar spinal stenosis- a prospective cohort study

Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction

Left Atrial Dyssynchrony During Sinus Rhythm: A Predictor For Incident Atrial Fibrillation/Flutter In Transthyretin Cardiac Amyloidosis

Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study

Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy

Cardiac transthyretin amyloidosis in patients with conduction system disease

Assessment of right ventricular myocardial stiffness by cardiac elastography in patients with transthyretin amyloidosis

Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters